OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we a...

Full description

Saved in:
Bibliographic Details
Published in:Neurogenetics 2011-02, Vol.12 (1), p.79-82
Main Authors: Becker, Matthijs L., Visser, Loes E., van Schaik, Ron H. N., Hofman, Albert, Uitterlinden, André G., Stricker, Bruno H. Ch
Format: Article
Language:English
Subjects:
Addictive behaviors
Adult and adolescent clinical studies
Aged
Aged, 80 and over
Alleles
Antiparkinson Agents - administration & dosage
Antiparkinson Agents - pharmacokinetics
Antiparkinson Agents - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cohort Studies
Drug addiction
Drug therapy
Female
Fundamental and applied biological sciences. Psychology
Genetics of eukaryotes. Biological and molecular evolution
Human Genetics
Humans
Levodopa - administration & dosage
Levodopa - pharmacokinetics
Male
Medical sciences
Molecular and cellular biology
Molecular Medicine
Neurosciences
Organic Cation Transporter 1 - genetics
Organic Cation Transporter 1 - metabolism
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson Disease - metabolism
Parkinson Disease - mortality
Parkinson's disease
Pharmacogenetics
Pharmacology
Polymorphism
Polymorphism, Single Nucleotide
Proportional Hazards Models
Proteins
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Short Communication
Survival Analysis
Vertebrates: nervous system and sense organs
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p  = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p  = 0.045).
ISSN:1364-6745
1364-6753
DOI:10.1007/s10048-010-0254-5